To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.
Awakn has a dual strategic focus:
- Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
- Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally.
Notable Highlights include:
- Strategic focus on better treating Addiction with psychedelics.
- World leading team focused on psychedelic drug and therapy research.
- Strong drug and therapy development pipeline, specifically targeting Addiction.
- Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery
- Closed $8.3M June 8
- BRAND NEW LISTING … commencing trading on NEO
Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.
Tags: addiction, CSE, ketamine, MDMA, mental health, NEO, Psychedelic, smallcap stocks, stocks, tsx, tsx-v